于澤奇++++++程世翔++++++涂悅++++++王婧怡++++++茍莞苓++++++張賽
[摘要] 目的 探討腦膠質(zhì)瘤患者瘤組織中Ki-67、Bcl-2、Bax和Caspase-3的表達(dá)水平及臨床意義。方法 選取2014年10月~2016年10月武警后勤學(xué)院附屬醫(yī)院手術(shù)切除的65例腦膠質(zhì)瘤組織切片。根據(jù)神經(jīng)系統(tǒng)腫瘤分類將其分為低級別膠質(zhì)瘤組34例和高級別膠質(zhì)瘤組31例,另取18例正常腦組織切片標(biāo)本作為對照組,比較3組標(biāo)本組織中Ki-67、Bcl-2、Bax和Caspase-3表達(dá)水平,并分析其與膠質(zhì)瘤惡性程度的相關(guān)性。 結(jié)果 隨著膠質(zhì)瘤病理級別的升高,Ki-67表達(dá)水平逐漸增強(qiáng),在正常腦組織、低、高級別膠質(zhì)瘤組中的表達(dá)陽性率分別為0、20.6%、77.4%,差異有統(tǒng)計學(xué)意義(P < 0.05),二者呈正相關(guān)性(Spearman相關(guān)系數(shù)為0.645,P < 0.05)。Bcl-2表達(dá)水平隨著膠質(zhì)瘤級別的升高而逐漸升高(6.2%、73.5%、100.0%),差異有統(tǒng)計學(xué)意義(P < 0.05),二者呈正相關(guān)性(Spearman相關(guān)系數(shù)為0.711,P < 0.05)。Bax表達(dá)水平隨著腦膠質(zhì)瘤級別的升高而逐漸降低(100.0%、82.4%、16.1%),差異有統(tǒng)計學(xué)意義(P < 0.05),二者呈負(fù)相關(guān)性(Spearman相關(guān)系數(shù)為-0.706,P < 0.05)。Caspase-3表達(dá)水平在低級別膠質(zhì)瘤組最高(0、100.0%、80.6%),隨病理級別的升高而逐漸降低(P < 0.05),二者呈負(fù)相關(guān)性(Spearman相關(guān)系數(shù)為-0.334,P < 0.05)。 結(jié)論 Ki-67與Bcl-2表達(dá)水平的上調(diào),Bax與Caspase-3表達(dá)水平的下調(diào),提示膠質(zhì)瘤病理級別越高。同時,根據(jù)Ki-67、Bcl-2、Bax和Caspase-3的表達(dá)水平可對膠質(zhì)瘤惡性程度進(jìn)行判斷,在一定程度上對患者預(yù)后評估具有重要指導(dǎo)意義。
[關(guān)鍵詞] 膠質(zhì)瘤;Ki-67;Bcl-2;Bax;Caspase-3
[中圖分類號] R739.41 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1673-7210(2017)02(b)-0009-04
[Abstract] Objective To investigate the expression levels of Ki-67, Bcl-2, Bax and Caspase-3 in patients with brain glioma and its clinical significance. Methods 65 cases with brain glioma in Affiliated Hospital of Logistics College of PAP from October 2014 to October 2016 were selected and divided into low grade glioma group (34 cases) and high grade glioma group (31 cases) according to the classification of tumors of the nervous system. Another 18 cases with normal brain tissue specimens were selected as the control group. The expression levels of Ki-67, Bcl-2, Bax and Caspase-3 were detected and compared. Besides, their correlations with the malignant degree of glioma were analyzed. Results As the pathological grade of glioma increasing, the expression level of Ki-67 increased. The positive rates in normal brain tissue, low and high grade glioma group were 0, 20.6% and 77.4%, respectively, with statistically significant difference (P < 0.05), and had a positive correlation with pathological grade (Spearman correlation coefficient was 0.645, P < 0.05). The expression level of Bcl-2 increased with the increase of glioma grade (6.2%, 73.5%, 100%), which showed a positive correlation with pathological grade (Spearman correlation coefficient was 0.711, P < 0.05). The expression level of Bax decreased with the increase of glioma grade (100.0%, 82.4%, 16.1%), which showed a negative correlation with pathological grade (Spearman correlation coefficient was -0.706, P < 0.05).The expression level of Caspase-3 in low grade glioma group was the highest among groups, which decreased with the increase of pathological grade and showed a negative correlation with pathological grade (Spearman correlation coefficient was -0.334, P < 0.05). Conclusion It shows the higher pathological grade of glioma is caused by the rising of the Ki-67 and Bcl-2 expression levels, as well as the decreasing of Bax and Caspase-3 expression levels. Meanwhile, it is very important in certain degree for the patients prognostic evaluation according to the judge the degree of glioma based on the Ki-67, Bcl-2, Bax and Caspase-3 expression levels.
[Key words] Glioma; Ki-67; Bcl-2; Bax; Caspase-3
膠質(zhì)瘤是人類神經(jīng)系統(tǒng)中最常見的一種原發(fā)惡性腫瘤[1]。膠質(zhì)瘤患者死亡率高,其原因與膠質(zhì)瘤侵入性生長方式有關(guān)[2]。Ⅰ~Ⅱ級膠質(zhì)瘤生長緩慢,病程長,但手術(shù)治療后復(fù)發(fā)率高。Ⅲ~Ⅳ級膠質(zhì)瘤生長迅速,病程短,且瘤體占位性效應(yīng)可引發(fā)患者嘔吐、視神經(jīng)萎縮和癲癇等[3]。膠質(zhì)瘤起病機(jī)制復(fù)雜,常與多種因素相關(guān)聯(lián)[4]。隨著醫(yī)療技術(shù)的不斷發(fā)展,對膠質(zhì)瘤的檢查、確診更為快捷。為了解Ki-67、Bcl-2、Bax和Caspase-3的表達(dá)水平與膠質(zhì)瘤間的相互聯(lián)系,本文通過免疫組化法對其進(jìn)行檢測,來探討是否可以根據(jù)Ki-67、Bcl-2、Bax和Caspase-3蛋白表達(dá)水平來指示患者的預(yù)后情況。
1 資料與方法
1.1 一般資料
選取2014年10月~2016年10月武警后勤學(xué)院附屬醫(yī)院(以下簡稱“我院”)腦膠質(zhì)瘤患者經(jīng)外科手術(shù)治療后切除的膠質(zhì)瘤標(biāo)本65例。將65例患者根據(jù)WHO 2007 年中樞神經(jīng)系統(tǒng)腫瘤分類標(biāo)準(zhǔn)[5]分為2類:①低級別膠質(zhì)瘤,腫瘤分級Ⅰ~Ⅱ級,其中星形細(xì)胞瘤15例,少枝膠質(zhì)細(xì)胞瘤19例。②高級別膠質(zhì)瘤,腫瘤分級Ⅲ~Ⅳ級,其中9例間變性星形細(xì)胞瘤,12例膠質(zhì)母細(xì)胞瘤,10例髓母細(xì)胞瘤。除此之外,取18例因外傷或者腦出血而進(jìn)行顱內(nèi)減壓的正常腦組織標(biāo)本作為對照。本次研究已獲我院倫理委員會的審批與認(rèn)可,所有標(biāo)本均取自有完整病歷資料并經(jīng)我院病理科證實的患者,且患者手術(shù)前未進(jìn)行放化療。
1.2 試劑與儀器
Ki-67兔抗人單克隆抗體、Bcl-2兔抗人單克隆抗體、Bax兔抗人單克隆抗體、Caspase-3兔抗人單克隆抗體(美國Abcam),免疫組化染色試劑盒、DAB試劑盒(北京中杉金橋生物技術(shù)有限公司),石蠟切片機(jī)(德國Leica),倒置相差顯微鏡(日本Nikon)。
1.3 免疫組織化學(xué)染色
所有標(biāo)本經(jīng)4%中性甲醛固定,脫水后石蠟包埋,將石蠟組織標(biāo)本行5 μm厚連續(xù)切片,經(jīng)脫蠟,EDTA抗原修復(fù),3%雙氧水消除內(nèi)源性過氧化物酶,血清封閉1 h后,分別滴加Ki-67、Bcl-2、Bax、Caspase-3一抗(稀釋濃度分別1∶100、1∶250、1∶100、1∶100)4℃孵育過夜,PBS清洗后滴加辣根過氧化物酶標(biāo)記二抗,室溫孵育1 h。DAB顯色,沖洗,蘇木精復(fù)染細(xì)胞核,常規(guī)梯度乙醇脫水,二甲苯透明,中性樹膠封片。用PBS液代替一抗做陰性對照。
1.4 陽性結(jié)果判定標(biāo)準(zhǔn)
Ki-67陽性判定:細(xì)胞核中出現(xiàn)棕黃色著色;Bcl-2細(xì)胞陽性判定:細(xì)胞核和細(xì)胞質(zhì)中出現(xiàn)黃色顆粒;Bax蛋白陽性判定:細(xì)胞質(zhì)中出現(xiàn)棕黃色顯色;Caspase-3陽性判定:細(xì)胞質(zhì)中發(fā)現(xiàn)棕黃色顆粒。標(biāo)本采用光學(xué)顯微鏡進(jìn)行觀察,由兩名資深病理科醫(yī)師采用雙盲法對結(jié)果進(jìn)行判定。每個腦組織切片隨機(jī)選擇5個不同的高倍視野,取200個腫瘤細(xì)胞,計算陽性細(xì)胞數(shù)及檢測陽性細(xì)胞染色程度。表達(dá)程度分為4級:①細(xì)胞呈現(xiàn)無顯色或出現(xiàn)陽性細(xì)胞數(shù)0%,表達(dá)程度為(-);②細(xì)胞呈現(xiàn)淺顯色或出現(xiàn)陽性細(xì)胞數(shù)<50%,表達(dá)程度為(+);③細(xì)胞呈現(xiàn)深顯色或出現(xiàn)陽性細(xì)胞數(shù)≥50%,表達(dá)程度為(++);④細(xì)胞呈現(xiàn)明顯或出現(xiàn)陽性細(xì)胞數(shù)≥85%,表達(dá)程度為(+++)。
1.5 統(tǒng)計學(xué)方法
采用SPSS 18.0軟件對數(shù)據(jù)進(jìn)行分析,組間Ki-67、Bcl-2、Bax和Caspase-3陽性率比較采用卡方檢驗,相關(guān)性分析采用Spearman法,以P < 0.05為差異有統(tǒng)計學(xué)意義。
2 結(jié)果
2.1 Ki-67在不同病理級別腦膠質(zhì)瘤組織及正常腦組織中的表達(dá)
Ki-67在正常腦組織中無表達(dá),陽性率為0%;在低級別膠質(zhì)瘤中表達(dá)水平升高,陽性率為20.6%;在高級別膠質(zhì)瘤中Ki-67表達(dá)水平最高,陽性率為77.4%,差異有統(tǒng)計學(xué)意義(P < 0.05)。Ki-67表達(dá)水平與膠質(zhì)瘤級別呈正相關(guān)性(Spearman相關(guān)系數(shù)為0.645,P < 0.05)。見表1。
2.2 Bcl-2在不同病理級別腦膠質(zhì)瘤組織及正常腦組織中的表達(dá)
Bcl-2在正常腦組織中表達(dá)陽性率為6.2%,在低級別膠質(zhì)瘤中陽性率為73.5%;在高級別膠質(zhì)瘤中的陽性率為100%,差異有統(tǒng)計學(xué)意義(P < 0.05)。Bcl-2表達(dá)水平與膠質(zhì)瘤惡性程度兩者存在正相關(guān)性(Spearman相關(guān)系數(shù)為0.711,P < 0.05)。見表2。
2.3 Bax在不同病理級別腦膠質(zhì)瘤組織及正常腦組織中的表達(dá)
Bax在正常腦組織中廣泛表達(dá),陽性率為100%;在低級別膠質(zhì)瘤中陽性率為82.4%;在高級別膠質(zhì)瘤中表達(dá)水平最低,陽性率為16.1%,差異有統(tǒng)計學(xué)意義(P < 0.05)。Bax表達(dá)水平與膠質(zhì)瘤級別呈負(fù)相關(guān)性(Spearman相關(guān)系數(shù)為-0.706,P < 0.05)。見表3。
2.4 Caspase-3在不同病理級別腦膠質(zhì)瘤組織及正常腦組織中的表達(dá)
Caspase-3在正常腦組織中陽性率為0%,在低級別膠質(zhì)瘤中陽性率為100.0%,在高級別膠質(zhì)瘤中陽性率為80.6%,差異有統(tǒng)計學(xué)意義(P < 0.05)。隨惡性程度的增高,Caspase-3表達(dá)水平有所降低(Spearman相關(guān)系數(shù)為-0.334,P < 0.05)。見表4。
3 討論
膠質(zhì)瘤是中樞神經(jīng)系統(tǒng)最常見的惡性腫瘤,常呈浸潤性生長,與周圍正常腦組織無明顯分界,術(shù)后易復(fù)發(fā),患者生存率低,危害性大[6]。研究表明,膠質(zhì)瘤不僅存在細(xì)胞增殖與分化障礙,同時還存在凋亡受阻,細(xì)胞增殖與凋亡的不平衡狀態(tài)是導(dǎo)致膠質(zhì)瘤惡性生長的基礎(chǔ)[7]。鑒于此,控制其生長速度成為治療膠質(zhì)瘤的關(guān)鍵。
Ki-67是存在于增殖細(xì)胞核內(nèi)的一種非組蛋白性核內(nèi)蛋白,在1983年由Scholzen等[8]研究Hodgkin淋巴瘤L428細(xì)胞系時發(fā)現(xiàn)。Ki-67定位于人類第10號染色體長臂上,由分子量為345 kD和395 kD的兩條多肽鏈組成,位于近核仁區(qū)[9]。它能識別G1晚期、S期和G2/M期細(xì)胞核的抗原,而處于靜息狀態(tài)的G0期和G1早期細(xì)胞缺乏此抗原。因此,臨床上常以此作為細(xì)胞增殖的標(biāo)記蛋白[10]。同時,多數(shù)研究表明Ki-67能夠可靠而迅速地反映腫瘤增殖率,與多種腫瘤的發(fā)生、進(jìn)展、轉(zhuǎn)移及預(yù)后相關(guān)[11]。本研究對65例膠質(zhì)瘤標(biāo)本及18例正常腦組織標(biāo)本進(jìn)行免疫組化,發(fā)現(xiàn)Ki-67表達(dá)水平隨膠質(zhì)瘤惡性程度的升高而表達(dá)明顯,與膠質(zhì)瘤病理級別呈正相關(guān)性(P < 0.05)。
近年來,隨著對膠質(zhì)瘤研究的不斷深入,人們發(fā)現(xiàn)Bcl-2和Bax是與細(xì)胞凋亡密切相關(guān)的蛋白,主要位于細(xì)胞質(zhì)內(nèi)[12]。Bcl-2為凋亡抑制因子[13],是從淋巴瘤中分離出來的原癌基因,Bcl-2基因定位于人類染色體18q21上;Bax為凋亡誘導(dǎo)因子[14],定位于人類染色體19q13上,其蛋白主要存在細(xì)胞質(zhì)中。當(dāng)受到凋亡信號刺激時,Bax便從細(xì)胞質(zhì)轉(zhuǎn)移至線粒體,再與線粒體膜上的Bcl-2相互作用從而發(fā)揮促凋亡作用。當(dāng)Bcl-2/Bax比值低時,形成Bax-Bax同源二聚體,促進(jìn)細(xì)胞凋亡[15];當(dāng)二者比值高時,可形成更穩(wěn)定的Bax-Bcl-2異源二聚體,抑制細(xì)胞凋亡[16],這種比率的變化是由于Bcl-2與Bax蛋白間競爭性二聚化作用的結(jié)果。在本研究中,Bcl-2與Bax均有明顯表達(dá),但隨膠質(zhì)瘤病理級別的升高,Bcl-2表達(dá)逐漸升高(P < 0.05),Bax表達(dá)逐漸降低(P < 0.05),Bcl-2/Bax比值相對升高,其抗凋亡活性增強(qiáng)。即膠質(zhì)瘤病理分級程度越高,癌細(xì)胞抗凋亡能力越強(qiáng)。由此可見,Bcl-2/Bax比值的測定對于臨床上膠質(zhì)瘤惡性程度的判定具有重要的參考價值。此外,Bcl-2還可調(diào)控線粒體滲透性轉(zhuǎn)換孔的開啟,抑制細(xì)胞色素色C,從而抑制Caspase-3的活化,同時Caspase-3的合成也受Bcl-2的調(diào)節(jié)抑制[17]。
Caspase-3是Caspase家族中最重要的凋亡執(zhí)行者之一,它通常以非活化的酶原形式存在于細(xì)胞質(zhì)中,在凋亡信號的刺激作用下被激活,可對多種蛋白底物進(jìn)行降解,從而在細(xì)胞凋亡過程中起重要作用[18]。研究發(fā)現(xiàn),Caspase-3可通過阻滯細(xì)胞周期,裂解細(xì)胞結(jié)構(gòu)物質(zhì),破壞平衡狀態(tài)及修復(fù)機(jī)制等促進(jìn)細(xì)胞凋亡的發(fā)生[19]。此外,Caspase-3還可降解凋亡抑制蛋白Bcl-2,使Caspase家族成員激活并被水解后發(fā)生級聯(lián)反應(yīng),最后在核小體連接處切割DNA鏈接片段,促進(jìn)細(xì)胞凋亡的發(fā)生[20]。在本研究中,Caspase-3蛋白表達(dá)陽性率在高級別膠質(zhì)瘤組明顯低于低級別膠質(zhì)瘤組,差異有統(tǒng)計學(xué)意義(P < 0.05),提示Caspase-3表達(dá)下調(diào)與膠質(zhì)瘤的惡性進(jìn)展密切相關(guān)。
綜上所述,Ki-67、Bcl-2、Bax和Caspase-3的表達(dá)與膠質(zhì)瘤的惡性進(jìn)展密切相關(guān),Ki-67、Bcl-2蛋白表達(dá)水平上調(diào),Bax、Caspase-3蛋白表達(dá)水平下調(diào),提示膠質(zhì)瘤病理級別越高。同時,Ki-67、Bcl-2、Bax和Caspase-3有可能成為膠質(zhì)瘤治療的有效靶點,為臨床上治療膠質(zhì)瘤提供新的思路。然而膠質(zhì)瘤發(fā)生、發(fā)展的根本原因可能還涉及多種凋亡基因,原癌基因及抑癌基因等,因此對膠質(zhì)瘤的調(diào)控機(jī)制還有待進(jìn)一步研究。
[參考文獻(xiàn)]
[1] He J,Ji X,Li Y,et al. Subchronic exposure of benzo(a)pyrene interferes with the expression of Bcl-2, Ki-67,C-myc and p53,Bax,Caspase-3 in sub-regions of cerebral cortex and hippocampus [J]. Exp Toxicol Pathol,2016,68(2-3):149-156.
[2] Jiang H,Zhao PJ,Su D,et al. Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo [J]. Mol Med Rep,2014,9(6):2265-2272.
[3] Marfia G,Navone SE,F(xiàn)anizzi C,et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma [J]. Cancer Med,2016,5(8):1783-1790.
[4] Zhang BX,Zhao X,Chen X,et al. Expression and clinical significance of Caspase-9,Bcl-2 and bax in basal-like breast carcinoma [J]. Shandong Medical Journal,2014,54(46):8-10.
[5] Rousseau A,Mokhtari K,Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system-what has changed?[J]. Curr Opin Neurol,2008,21(6):720-727.
[6] Khan MN,Sharma AM,Pitz M,et al. High-grade glioma management and response assessment-recent advances and current challenges [J]. Curr Oncol,2016,23(4):e383-391.
[7] Iwamaru A,Iwado E,Kondo S,et al. Eupalmerin acetate,a novel anticancer agent from Caribbean gorgonian octocorals,induces apoptosis in malignant glioma cells via the c-Jun NH2-terminal kinase pathway [J]. Mol Cancer Ther,2007,6(1):184-192.
[8] Scholzen T,Gerdes J. The Ki-67 protein:from the know and the unknown [J]. J Cell Physiol,2000,182(3):311-322.
[9] Duchrow M,Schlüter C,Wohlenberg C,et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67 [J]. Cell Prolif,1996,29(1):1-12.
[10] Ma C,Li Y,Zhang X,et al. Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma [J]. J Int Med Res,2014,42(1):198-204.
[11] Mullerat J,Deroide F,Winslet MC,et al. Proliferation and p53 expression in anal cancer precursor lesions [J]. Anticancer Res,2003,23(3C):2995-2999.
[12] Yang Y,Zong M,Xu W,et al. Natural pyrethrins induces apoptosis in human hepatocyte cells via Bax- and Bcl-2-mediated mitochondrial pathway [J]. Chem Biol Interact,2016(262):38-45.
[13] Yu Y,Sun L,Ren N,et al. Down-expression of F box only protein 8 correlates with tumor grade and poor prognosis in human glioma [J]. Int J Clin Exp Pathol,2014,7(11):8071-8076.
[14] Akiyama Y,Komiyama M,Miyata H,et al. Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients [J]. Oncol Rep,2014,31(4):1683-1690.
[15] Chang G,Zhang P,Ye L,et al. Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model [J]. Eur J Pharmacol,2013,718(1-3):105-113.
[16] Cartron PF,Juin P,Oliver L,et al. Nonredundant role of Bax and Bak in Bid-mediated apoptosis [J]. Mol Cell Biol,2003,23(13):4701-4712.
[17] Cheng AC,Jian CB,Huang YT,et al. Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production,cytochrome c release,and caspases activation in human leukemia cells [J]. Food Chem Toxicol,2007,45(11):2206-2218.
[18] Burgess JT,Bolderson E,Adams MN,et al. Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response [J]. Cell Death Dis,2016,7(11):e2469.
[19] Fan TJ,Han LH,Cong RS,et al. Caspase family proteases and apoptosis [J]. Acta Biochim Biophys Sin:Shanghai,2005,37(11):719-727.
[20] Karran L,Dyer MJ. Proteolytic cleavage of molecules involved in cell death or survival pathways:a role in the control of apoptosis?[J]. Crit Rev Eukaryot Gene Expr,2001,11(4):269-277.